InsiderTrades.com logo
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.
Bruce L. A. Carter net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Bruce Carter Biography and Net Worth

Director of Mirati Therapeutics
Bruce is an affiliate Professor in the Department of Biotechnology at the University of Washington, Seattle—a position he has held since 1986. He currently serves on the board of directors of Mirati and Enanta Pharmaceuticals, publicly held biopharmaceutical companies, and Dr. Reddy’s Laboratories, a publicly held pharmaceutical company based in India. Bruce also serves as Chairman of the board at the TB Alliance.

Prior to his current appointment, Bruce served as Executive Chairman of the board at Immune Design Corp. from 2009 to 2011, later serving as Chairman of the board until 2012 and as a member of the board until 2015. Between 1986 and 1994, Bruce served as Vice President of Research and Development as well as Chief Executive Officer at ZymoGenetics, Inc. In 1988, Novo Nordisk A/S acquired ZymoGenetics, leading to Bruce appointment as Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk in 1994. In 2000, Bruce led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom.* Bruce also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a lecturer in genetics at Trinity College, University of Dublin from 1975 to 1982.

He received a Ph.D. in Microbiology from Queen Elizabeth College, University of London, and a B.Sc. with Honors in Botany from the University of Nottingham, England.

What is Bruce L. A. Carter's net worth?

The estimated net worth of Bruce L. A. Carter is at least $353,432.70 as of August 12th, 2022. Mr. Carter owns 6,021 shares of Mirati Therapeutics stock worth more than $353,433 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Carter may own. Learn More about Bruce L. A. Carter's net worth.

How do I contact Bruce L. A. Carter?

The corporate mailing address for Mr. Carter and other Mirati Therapeutics executives is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Mirati Therapeutics can also be reached via phone at (858) 332-3410 and via email at [email protected]. Learn More on Bruce L. A. Carter's contact information.

Has Bruce L. A. Carter been buying or selling shares of Mirati Therapeutics?

Bruce L. A. Carter has not been actively trading shares of Mirati Therapeutics within the last three months. Most recently, Bruce L. A. Carter sold 10,000 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $85.49, for a transaction totalling $854,900.00. Following the completion of the sale, the director now directly owns 6,021 shares of the company's stock, valued at $514,735.29. Learn More on Bruce L. A. Carter's trading history.

Who are Mirati Therapeutics' active insiders?

Mirati Therapeutics' insider roster includes Charles Baum (CEO), Bruce Carter (Director), Julie Cherrington (Director), Jamie Christensen (EVP), Daniel Faga (COO), Henry Fuchs (Director), Benjamin Hickey (EVP), Craig Johnson (Director), and Vickie Reed (CAO). Learn More on Mirati Therapeutics' active insiders.

Are insiders buying or selling shares of Mirati Therapeutics?

In the last year, Mirati Therapeutics insiders bought shares 2 times. They purchased a total of 1,212,231 shares worth more than $33,700,021.80. In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 15,092 shares worth more than $718,580.02. The most recent insider tranaction occured on January, 16th when EVP Benjamin Hickey sold 1,597 shares worth more than $94,254.94. Insiders at Mirati Therapeutics own 3.3% of the company. Learn More about insider trades at Mirati Therapeutics.

Information on this page was last updated on 1/16/2024.

Bruce L. A. Carter Insider Trading History at Mirati Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2022Sell10,000$85.49$854,900.006,021View SEC Filing Icon  
4/5/2021Sell2,250$177.11$398,497.505,725View SEC Filing Icon  
2/2/2021Sell2,250$191.12$430,020.00
11/20/2019Sell3,000$94.74$284,220.003,000View SEC Filing Icon  
8/21/2019Sell3,000$89.24$267,720.003,000View SEC Filing Icon  
5/22/2019Sell3,000$75.20$225,600.003,000View SEC Filing Icon  
2/20/2019Sell3,000$73.64$220,920.003,000View SEC Filing Icon  
See Full Table

Bruce L. A. Carter Buying and Selling Activity at Mirati Therapeutics

This chart shows Bruce L A Carter's buying and selling at Mirati Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mirati Therapeutics Company Overview

Mirati Therapeutics logo
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $58.70
Low: $58.70
High: $58.70

50 Day Range

MA: $58.82
Low: $58.70
High: $59.28

2 Week Range

Now: $58.70
Low: $27.30
High: $64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77
Global crypto currency reset (41 major banks signed up)
From Stansberry Research   |   Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
 Here's everything you need to know.